Piper Sandler lowered the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) to $81 from $110 while keeping an ...

Chardan slashed the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) on May 27, lowering it to $18 from $40 ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL ...

On May 27, analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on Prothena Corporation plc (NASDAQ: PRTA) but ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Prothena halts birtamimab development after Phase 3 trial fails to meet endpoints in AL amyloidosis patients; cost cuts and ...

Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce ...

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

Prothena (PRTA) stock drops as a late-stage trial for the company's lead candidate fails, prompting Oppenheimer and Jefferies ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

Accelerated diagnoses, diversified pipelines, regulatory convergence, strategic partnerships, value-based access models, and ...

The Chattanooga Heart Institute at CHI Memorial announced the opening a new center aimed at detecting and treating an often ...